AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma

BACKGROUND: Few prospective studies have assessed the role of bevacizumab and included a control arm with standard treatments for recurrent glioblastoma. We conducted a noncomparative phase II trial (AVAREG) to examine the efficacy of bevacizumab or fotemustine in this setting. METHODS: Eligible pat...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Brandes, Alba A., Finocchiaro, Gaetano, Zagonel, Vittorina, Reni, Michele, Caserta, Claudia, Fabi, Alessandra, Clavarezza, Matteo, Maiello, Evaristo, Eoli, Marica, Lombardi, Giuseppe, Monteforte, Marta, Proietti, Emanuela, Agati, Raffaele, Eusebi, Vincenzo, Franceschi, Enrico
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2016
Matèries:
Clinical Investigation
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4998997/
https://ncbi.nlm.nih.gov/pubmed/26951379
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/now035
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars